IS THE CHOP REGIMEN A GOOD TREATMENT FOR ADVANCED CLL - RESULTS FROM 2 RANDOMIZED CLINICAL-TRIALS

被引：0

作者：

FENAUX, P ^{[1
]}

MOREL, P ^{[1
]}

BAUTERS, F ^{[1
]}

PIGUET, H ^{[1
]}

MONCONDUIT, M ^{[1
]}

TILLY, F ^{[1
]}

DESABLENS, B ^{[1
]}

CLAISSE, JF ^{[1
]}

ADJIZIAN, JC ^{[1
]}

POTRON, G ^{[1
]}

PIGNON, B ^{[1
]}

LEPORRIER, M ^{[1
]}

TROUSSARD, X ^{[1
]}

REMAN, O ^{[1
]}

BINET, JL ^{[1
]}

DIGHIERO, G ^{[1
]}

MALOUM, K ^{[1
]}

MERLEBERAL, H ^{[1
]}

RAPHAEL, M ^{[1
]}

REISENLEITER, M ^{[1
]}

LINASSIER, C ^{[1
]}

LAMAGNERE, JP ^{[1
]}

JAUBERT, J ^{[1
]}

VASSELOM, C ^{[1
]}

LEBLAY, R ^{[1
]}

JACOMY, D ^{[1
]}

GROSBOIS, B ^{[1
]}

DREYFUS, B ^{[1
]}

GUILHOT, F ^{[1
]}

VAUGIER, G ^{[1
]}

SOUTEYRAND, P ^{[1
]}

LEPEU, G ^{[1
]}

TOUCHAIS, AM ^{[1
]}

BOUDJERRA, N ^{[1
]}

BORDESSOULE, M ^{[1
]}

SCHMIDT, J ^{[1
]}

FACQUETDANIS, J ^{[1
]}

SEBBAN, C ^{[1
]}

ALLARD, C ^{[1
]}

MURGUE, B ^{[1
]}

SCHVED, JF ^{[1
]}

ARNAUD, A ^{[1
]}

CASSASSUS, P ^{[1
]}

LEPRISE, PY ^{[1
]}

DOR, JF ^{[1
]}

TURPIN, F ^{[1
]}

SOLALCELIGNY, P ^{[1
]}

TERTIAN, G ^{[1
]}

BERNARD, JF ^{[1
]}

JAMES, JM ^{[1
]}

机构：

[1] CTR HOSP REG & UNIV LILLE,F-59037 LILLE,FRANCE

来源：

LEUKEMIA & LYMPHOMA | 1994年 / 13卷 / 5-6期

关键词：

CHOP REGIMEN; TREATMENT; ADVANCED CLL; LYMPHOCYTIC LEUKEMIA; RANDOMIZED CLINICAL TRIALS;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Between 1985 and 1990, the French Cooperative Group on Chronic Lymphocytic Leukemia (CLL) randomized 287 stage B patients between intermittent chlorambucil plus prednisone (n=140) or CHOP (n=147), and 90 stage C patients between CHOP (n=44) or CHOP plus methotrexate (n=46). In stage B, although treatment response was improved with CHOP (p=0.007, chi-square test), no difference in survival was observed between the two randomized groups (p=0.33, score test). In stage C, no differences in treatment response and survival were shown, with median survival close to that reported with CHOP in the previous CLL-80 trial. These results associated with those from other groups raise the question whether the CHOP regimen, which has been consistently shown to improve response to therapy, is an effective treatment in advanced CLL patients.

引用

页码：449 / 456

页数：8

共 30 条

[21] Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence:: Results of two randomized clinical trials 10.1038/sj.npp.1300861
Lerman, C
Jepson, C
Wileyto, EP
Epstein, LH
Rukstalis, M
Patterson, F
Kaufmann, V
Restine, S
Hawk, L
Niaura, R
Berrettini, W
NEUROPSYCHOPHARMACOLOGY, 2006, 31 (01) : 231 - 242
[22] Exploring heterogeneities of cardiovascular efficacy and effectiveness of SGLT2 inhibitors in patients with type 2 diabetes: an umbrella review of evidence from randomized clinical trials versus real-world observational studies
Seo, Bojung
Su, Jialin
Song, Yiqing
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (08) : 1205 - 1216
[23] Exploring heterogeneities of cardiovascular efficacy and effectiveness of SGLT2 inhibitors in patients with type 2 diabetes: an umbrella review of evidence from randomized clinical trials versus real-world observational studies
Bojung Seo
Jialin Su
Yiqing Song
European Journal of Clinical Pharmacology, 2022, 78 : 1205 - 1216
[24] Treatment with delgocitinib cream improves itch, pain and other signs and symptoms of chronic hand eczema: Results from the Hand Eczema Symptom Diary in a phase IIb randomized clinical trial
Bauer, Andrea
Thyssen, Jacob P. P.
Buhl, Timo
Nielsen, Thor Schutt Svane
Larsen, Lotte Seiding
Osterskov, Anne Birk
Agner, Tove
CONTACT DERMATITIS, 2023, 89 (01) : 46 - 53
[25] Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: A meta-analysis of individual patient data from 10 double-blind, randomized clinical trials
Papakostas, George I.
Trivedi, Madhukar H.
Alpert, Jonathan E.
Seifert, Cheryl A.
Krishen, Alok
Goodale, Elizabeth P.
Tucker, Vivian L.
JOURNAL OF PSYCHIATRIC RESEARCH, 2008, 42 (02) : 134 - 140
[26] Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer: a meta-analysis and systemic review of randomized clinical trials
Wenjie Zhu
Binghe Xu
Frontiers of Medicine, 2021, 15 : 208 - 220
[27] Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a meta-analysis and systemic review of randomized clinical trials
Zhu, Wenjie
Xu, Binghe
FRONTIERS OF MEDICINE, 2021, 15 (02) : 208 - 220
[28] Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis Results From a Phase 2a Clinical Trial
Almon, Einat
Shaaltiel, Yoseph
Sbeit, Wisam
Fich, Alex
Schwartz, Doron
Waterman, Mattitiahu
Szlaifer, Mali
Reuveni, Hadar
Amit-Cohen, Bat-chen
Alon, Sari
Chertkoff, Raul
Paz, Alona
Ilan, Yaron
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2021, 55 (02) : 134 - 140
[29] Statistical analysis plan for pooled individual patient data from two landmark randomized trials (INTERACT2 and ATACH-II) of intensive blood pressure lowering treatment in acute intracerebral hemorrhage
Moullaali, Tom J.
Wang, Xia
Martin, Renee' H.
Shipes, Virginia B.
Qureshi, Adnan I.
Anderson, Craig S.
Palesch, Yuko Y.
INTERNATIONAL JOURNAL OF STROKE, 2019, 14 (03) : 321 - 328
[30] Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron
Ison, Michael G.
Popejoy, Myra
Evgeniev, Nikolay
Tzekova, Maria
Mahoney, Kathryn
Betancourt, Natalia
Li, Yong
Gupta, Deepali
Narayan, Kristin
Hershberger, Ellie
Connolly, Lynn E.
Yalcin, Ilker
Das, Anita F.
Genge, John
Smith, Michelle
Campanaro, Ed
Hawn, Pamela
Schmidt, Pete
Muniz, Heloisa Costa Ravagnani
OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (06):

← 1 2 3 →